Fintel reports that on February 13, 2025, Cantor Fitzgerald initiated coverage of GH Research (NasdaqGM:GHRS) with a ...

Shares of GH Research PLC GHRS have rallied 54.8% in a week after the company, on Feb. 3, 2025, announced that it has met the ...

周四 - Cantor Fitzgerald对GH Research PLC (NASDAQ: GHRS )给予"增持"评级，目标价设定为14.00美元。这一新的评级基于GHRS的GH001（一种吸入式5-MeO-DMT疗法）有望成为难治性抑郁症（TRD）标准疗法的潜力。Cantor ...

Cantor Fitzgerald analyst Charles Duncan initiated coverage of GH Research (GHRS) with an Overweight rating and no price target GH Research is ...

We recently compiled a list of the Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where GH Research PLC (NASDAQ:GHRS) stands against ...

Shares of GH Research PLC GHRS have rallied 54.8% in a week after the company, on Feb. 3, 2025, announced that it has met the primary goal in a mid-stage study of its investigational, inhalable ...

GH Research's Phase 2b trial of GH001 for treatment-resistant depression met its primary endpoint, showing significant efficacy and a favorable safety profile.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

GH Research (GHRS) announced the commencement of an underwritten public offering of $150M of ordinary shares. All of the ordinary shares are to ...